סימבקסון 40

国: イスラエル

言語: ヘブライ語

ソース: Ministry of Health

有効成分:

SIMVASTATIN

から入手可能:

DEXCEL PHARMA TECHNOLOGIES LTD

ATCコード:

C10AA01

医薬品形態:

קפליות

構図:

SIMVASTATIN 40 MG

投与経路:

פומי

処方タイプ:

מרשם נדרש

製:

DEXCEL LTD, ISRAEL

治療群:

SIMVASTATIN

治療領域:

SIMVASTATIN

適応症:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

製品概要:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

承認日:

2020-04-30